OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Pharmacy and Pharmaceutical Sciences is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
The need to redefine diabetic cardiomyopathy as a unique clinical entity that requires pharmacotherapy	103
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments	80
Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea.	42
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs	36
Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition	35
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred	35
Effect of Oregon grape root extracts on P-glycoprotein mediated transport in in vitro cell lines	31
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials	28
Effect of Concomitant Drug Use on the Onset and Exacerbation of Diabetes Mellitus in Everolimus-Treated Cancer	26
Applications of Exhaled Breath Condensate Analysis for Drug Monitoring and Bioequivalence Study of Inhaled Drugs	22
Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome	20
Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome	19
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy	18
Dissolution-permeation approach for biopharmaceutical evaluation: a feasibility study using naproxen	17
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System	16
From fasting to fat reshaping: exploring the molecular pathways of intermittent fasting-induced adipose tissue remodeling	16
Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines	16